Citigroup Downgrades Accendra Health to Neutral, Lowers Price Target to $1.5

Benzinga Newsdesk www.benzinga.com Negative 86.4%

Neg 86.4% Neu 0% Pos 0%

Citigroup analyst Daniel Grosslight downgrades Accendra Health (NYSE:ACH) from Buy to Neutral and lowers the price target from $4.5 to $1.5.